A
Aurelia Dinut
Researcher at French Institute of Health and Medical Research
Publications - 6
Citations - 600
Aurelia Dinut is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Sorafenib & Population. The author has an hindex of 3, co-authored 6 publications receiving 398 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Valérie Vilgrain,Valérie Vilgrain,Helena Pereira,Eric Assenat,Boris Guiu,Alina Diana Ilonca,Georges-Philippe Pageaux,Annie Sibert,Mohamed Bouattour,Rachida Lebtahi,Wassim Allaham,Hélène Barraud,Valérie Laurent,Elodie Mathias,Jean-Pierre Bronowicki,Jean-Pierre Tasu,Rémy Perdrisot,Christine Silvain,René Gerolami,Olivier Mundler,Jean-François Seitz,Vincent Vidal,Christophe Aubé,Frédéric Oberti,Olivier Couturier,Isabelle Brenot-Rossi,Jean-Luc Raoul,Anthony Sarran,Charlotte Costentin,Emmanuel Itti,Alain Luciani,Alain Luciani,René Adam,Maïté Lewin,Didier Samuel,Maxime Ronot,Maxime Ronot,Aurelia Dinut,Laurent Castera,Laurent Castera,Gilles Chatellier,Gilles Chatellier,Elisabeth Delhom Christol,Alina D. Ilonca,Julie Lonjon,Mohamed Abdel-Rehim,Arnaud Dieudonné,Christophe Bazin,Carine Chagneau-Derrode,Patrick Borentain,Antoine Bouvier,Laurent Vervueren,Julia Chalaye,Hicham Kobeiter,Julien Edeline,Etienne Garin,Yan Rolland,Isabelle Archambeaud,T. Eugène,Eric Frampas,Christophe Cassinotto,Martine Guyot,Jean-Baptiste Hiriart,Bruno Lapuyade,Julien Vergniol,Philippe Bachellier,Julien Detour,Bernard Duclos,Michel Greget,Francois Habersetzer,Alessio Imperiale,Philippe Merle,Agnès Rode,Julie Morvan,Eric Nguyen-Khac,Thierry Yzet,G. Baudin,Patrick Chevallier,Abakar Mahamat,Thierry Piche,Micheline Razzouk,Patrick Hillon,Romaric Loffroy,Michel Toubeau,Julie Vincent,Gabriele Barabino,Nadia Bouarioua,Muriel Cuilleron,Marie Ecochard,Nathalie Prevot-Bitot,Vincent Leroy,J. Roux,Christian Sengel,Valérie Bourcier,Nathalie Ganne-Carrié,Olivier Seror,Sylvie Costo,Thong Dao,Jean-Pierre Pelage,Jérôme Dumortier,Francesco Giammarile,Pierre-Jean Valette,Nadia Ghazzar,Olivier Pellerin,Julien Taieb,Pierre Weinmann,Alexandra Heurgue-Berlot,Claude Marcus,Daniele Sommacale,Maria-Angéla Castilla-Lièvre,Sophie Maitre,Lysiane Marthey +111 more
TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.
Journal ArticleDOI
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Benjamin Planquette,Benjamin Planquette,Laurent Bertoletti,Anaïs Charles-Nelson,Silvy Laporte,Claire Grange,Isabelle Mahé,Isabelle Mahé,Gilles Pernod,Antoine Elias,Francis Couturaud,Nicolas Falvo,Marie Antoinette Sevestre,Valérie Ray,Alexis Burnod,N. Brebion,Pierre-Marie Roy,Miruna Timar-David,Sandro Aquilanti,Joël Constans,Alessandra Bura-Riviere,D. Brisot,Gilles Chatellier,Olivier Sanchez,Olivier Sanchez,Guy Meyer,Guy Meyer,Philippe Girard,Patrick Mismetti,Hervé Decousus,Aurélien Delluc,Christine Laneau,Aurelia Dinut,Philippe Aegerter,Joseph Emmerich,Emmanuel Messas,Marie-Pierre Revel,Sandrine Acassat,Ludovic Plaisance,Géraldine Poenou,Bernard Imbert,Nora Zenati,Raphael Le Mao,Clément Hoffmann,Marie Elias,Romaric Loffroy,Maud Jandot,Marie-Antoinette Sevestre,Santhi Samy Modéliar Rémond,Thomas Moumneh,Samir Henni,Miruna Timor-David,Carine Boulon +52 more
TL;DR: In this paper, a randomized open-label non-inferiority trial was conducted to evaluate the effectiveness of direct oral anticoagulants (DOACs) compared to low-molecular-weight heparin for treating cancer-associated venous thromboembolism (VTE).
Journal ArticleDOI
VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials
Val Gebski,Emma Gibbs,Mihir Gandhi,Gilles Chatellier,Aurelia Dinut,Helena Pereira,Pierce Kh Chow,Valérie Vilgrain +7 more
TL;DR: This meta-analysis of the SIRveNIB and SARAH randomized trials will allow the effect of the interventions to be explored with improved reliability/precision with respect to prespecified patient and intervention-level characteristics and Pooling of toxicity results will allow for robust safety profiles to be established for both therapies.
Journal ArticleDOI
LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial
Mohamed Bouattour,Eric Assenat,Boris Guiu,Diana Ilonca Alina,Georges-Philippe Pageaux,Annie Sibert,Rachida Lebtahi,Wassim Allaham,Hélène Barraud,Valérie Laurent,Elodie Mathias,Jean-Pierre Bronowicki,Jean-Pierre Tasu,Rémy Perdrisot,Christine Silvain,René Gerolami,Olivier Mundler,Jean-François Seitz,Vincent Vidal,Christophe Aubé,Frédéric Oberti,Olivier Couturier,Isabelle Brenot-Rossi,Jean-Luc Raoul,Anthony Sarran,Charlotte Costentin,Emmanuel Itti,Alain Luciani,Alain Luciani,René Adam,Maïté Lewin,Didier Samuel,Maxime Ronot,Aurelia Dinut,Helena Pereira,Laurent Castera,Laurent Castera,Gilles Chatellier,Gilles Chatellier,Valérie Vilgrain,Valérie Vilgrain +40 more
TL;DR: The SARAH Trial Group Assistance Publique Hô Pitaux de Paris, Hôpitaux Universitaires Paris Nord Val de Seine, and the SARAH trial group are revealed.
Journal ArticleDOI
From prospective clinical trial to reducing social inequalities in health: The DESSEIN trial, concept and design of a multidisciplinary study in precarious patients with breast cancer.
Charlotte Ngo,Aurelia Dinut,Audrey Bochaton,Hélène Charreire,Caroline Desprès,Sandrine Baffert,Fabrice Lecuru,Gilles Chatellier,Gilles Chatellier +8 more
TL;DR: This study aims to evaluate the impact of precariousness on care pathways, treatment and recovery phase according to a multidisciplinary analysis and provide a better understanding of how contextual factors, combined with individual factors, can influence the course of health and thus the stage of the disease at diagnosis.